Histone lactylation-boosted ALKBH3 potentiates tumor progression and diminished promyelocytic leukemia protein nuclear condensates by m1A demethylation of SP100A
Nucleic Acids Research · 2024
DOI: 10.1093/nar/gkad1193 ↗Kurz gefasst
Fachartikel in der Zeitschrift Nucleic Acids Research, 2024. Verfasst von Xiang Gu und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Ophthalmology, Shanghai Key Laboratory of Orbital Diseases and Ocular Oncology, Shanghai Ninth People's Hospital, Shanghai Jiao Tong Un…. Hauptthemen laut MEDLINE: AlkB Homolog 3, Alpha-Ketoglutarate-Dependent Dioxygenase, Histones, Melanoma, Antigens, Nuclear. Die Arbeit wurde bisher 142-mal zitiert (Crossref) und nennt 57 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Science and Technology Commission of Shanghai, China Postdoctoral Science Foundation.
Abstract (Originalsprache)
Albeit N1-Methyladenosine (m1A) RNA modification represents an important regulator of RNA metabolism, the role of m1A modification in carcinogenesis remains enigmatic. Herein, we found that histone lactylation enhances ALKBH3 expression and simultaneously attenuates the formation of tumor-suppressive promyelocytic leukemia protein (PML) condensates by removing the m1A methylation of SP100A, promoting the malignant transformation of cancers. First, ALKBH3 is specifically upregulated in high-risk ocular melanoma due to excessive histone lactylation levels, referring to m1A hypomethylation status. Moreover, the multiomics analysis subsequently identified that SP100A, a core component for PML bodies, serves as a downstream candidate target for ALKBH3. Therapeutically, the silencing of ALKBH3 exhibits efficient therapeutic efficacy in melanoma both in vitro and in vivo, which could be reversed by the depletion of SP100A. Mechanistically, we found that YTHDF1 is responsible for recognition of the m1A methylated SP100A transcript, which increases its RNA stability and translational efficacy. Conclusively, we initially demonstrated that m1A modification is necessary for tumor suppressor gene expression, expanding the current understandings of dynamic m1A function during tumor progression. In addition, our results indicate that lactylation-driven ALKBH3 is essential for the formation of PML nuclear condensates, which bridges our knowledge of m1A modification, metabolic reprogramming, and phase-separation events.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Ophthalmology, Shanghai Key Laboratory of Orbital Diseases and Ocular Oncology, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200011, People's Republic of Chi…
ORCID-Profile: Xianqun Fan, Peiwei Chai
Förderung
- National Natural Science Foundation of China
- Science and Technology Commission of Shanghai
- China Postdoctoral Science Foundation
- Shanghai Key Clinical Specialty, Shanghai Eye Disease Research Center
- Innovative Research Team of High-level Local Universities in Shanghai
- Shanghai Municipal Health Commission
Zitieren
APA
Gu, X., Zhuang, A., Yu, J., Yang, L., Ge, S., Ruan, J., Jia, R., Fan, X., & Chai, P. (2024). Histone lactylation-boosted ALKBH3 potentiates tumor progression and diminished promyelocytic leukemia protein nuclear condensates by m1A demethylation of SP100A. Nucleic Acids Research. https://doi.org/10.1093/nar/gkad1193
Vancouver
Gu X, Zhuang A, Yu J, Yang L, Ge S, Ruan J, et al. Histone lactylation-boosted ALKBH3 potentiates tumor progression and diminished promyelocytic leukemia protein nuclear condensates by m1A demethylation of SP100A. Nucleic Acids Research. 2024. doi:10.1093/nar/gkad1193
BibTeX
@article{Gu2024,
author = {Gu, Xiang and Zhuang, Ai and Yu, Jie and Yang, Ludi and Ge, Shengfang and Ruan, Jing and Jia, Renbing and Fan, Xianqun and Chai, Peiwei},
title = {Histone lactylation-boosted ALKBH3 potentiates tumor progression and diminished promyelocytic leukemia protein nuclear condensates by m1A demethylation of SP100A},
journal = {Nucleic Acids Research},
year = {2024},
doi = {10.1093/nar/gkad1193}
}
EUVIMED